JP2003533489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003533489A5 JP2003533489A5 JP2001583799A JP2001583799A JP2003533489A5 JP 2003533489 A5 JP2003533489 A5 JP 2003533489A5 JP 2001583799 A JP2001583799 A JP 2001583799A JP 2001583799 A JP2001583799 A JP 2001583799A JP 2003533489 A5 JP2003533489 A5 JP 2003533489A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- microorganism
- adjuvant
- commensal
- mucosal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000005700 microbiome Species 0.000 description 13
- 239000002671 adjuvant Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 4
- 206010065764 Mucosal infection Diseases 0.000 description 3
- 210000000447 Th1 cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU7612 | 1994-08-24 | ||
| AUPQ7612A AUPQ761200A0 (en) | 2000-05-19 | 2000-05-19 | Compositions and methods for treatment of mucosal infections |
| AUPQ7612 | 2000-05-19 | ||
| PCT/AU2001/000588 WO2001087332A1 (en) | 2000-05-19 | 2001-05-21 | Compositions and methods for treatment of mucosal infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012080832A Division JP2012153706A (ja) | 2000-05-19 | 2012-03-30 | 粘膜感染症の処置のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003533489A JP2003533489A (ja) | 2003-11-11 |
| JP2003533489A5 true JP2003533489A5 (enExample) | 2008-07-10 |
| JP5567756B2 JP5567756B2 (ja) | 2014-08-06 |
Family
ID=3821690
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001583799A Expired - Fee Related JP5567756B2 (ja) | 2000-05-19 | 2001-05-21 | 粘膜感染症の処置のための組成物および方法 |
| JP2012080832A Pending JP2012153706A (ja) | 2000-05-19 | 2012-03-30 | 粘膜感染症の処置のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012080832A Pending JP2012153706A (ja) | 2000-05-19 | 2012-03-30 | 粘膜感染症の処置のための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8637051B2 (enExample) |
| EP (1) | EP1305042B1 (enExample) |
| JP (2) | JP5567756B2 (enExample) |
| KR (1) | KR20030019389A (enExample) |
| CN (1) | CN1437480A (enExample) |
| AT (1) | ATE535284T1 (enExample) |
| AU (1) | AUPQ761200A0 (enExample) |
| BR (1) | BR0110971A (enExample) |
| CA (1) | CA2409813C (enExample) |
| WO (1) | WO2001087332A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ761200A0 (en) * | 2000-05-19 | 2000-06-15 | Hunter Immunology Limited | Compositions and methods for treatment of mucosal infections |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| TWI350174B (en) * | 2003-03-12 | 2011-10-11 | Wyeth Corp | Adjuvanted bovine vaccines |
| WO2005077409A1 (en) * | 2004-02-18 | 2005-08-25 | The University Of Newcastle Research Associates Limited | A vaccine formulated for administration to mucosa of the lungs |
| US7862808B2 (en) | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
| EP1793848A4 (en) * | 2004-08-17 | 2008-06-11 | Hunter Immunology Ltd | METHOD OF DETERMINING A DOSAGE FOR ORAL INACTIVE VACCINE |
| ATE526978T1 (de) | 2004-08-17 | 2011-10-15 | Hunter Immunology Ltd | Verfahren zur herstellung von oral abgetöteten vakzinen |
| US7303745B2 (en) * | 2005-04-15 | 2007-12-04 | Bristol-Myers Squibb Company | Method for preventing or treating the development of respiratory allergies |
| US20060233762A1 (en) * | 2005-04-15 | 2006-10-19 | Mcmahon Robert J | Method for treating or preventing systemic inflammation in formula-fed infants |
| US8857659B2 (en) | 2010-03-18 | 2014-10-14 | Eveready Battery Company, Inc. | Button cell battery dispenser package |
| EP2585094B1 (en) * | 2010-06-25 | 2018-08-01 | INSERM - Institut National de la Santé et de la Recherche Médicale | Flagellin polypeptide as tlr5 agonist for use in the treatment of respiratory tract infections |
| US20140275420A1 (en) | 2011-08-22 | 2014-09-18 | Carnegie Mellon University | Atom transfer radical polymerization under biologically compatible conditions |
| CA3254723A1 (en) * | 2014-05-02 | 2025-04-15 | Qu Biologics Inc | ANTIMICROBIAL IMMUNOMODULATION |
| US9982070B2 (en) | 2015-01-12 | 2018-05-29 | Carnegie Mellon University | Aqueous ATRP in the presence of an activator regenerator |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| AU2021252164A1 (en) | 2020-04-09 | 2022-12-15 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
| CN111529703B (zh) * | 2020-06-17 | 2023-09-15 | 湖南循天然营养有限公司 | 一种组合物及其制备方法与在制备免疫佐剂中的应用 |
| WO2024234034A1 (en) * | 2023-05-12 | 2024-11-21 | Biomune Pty Ltd | Compositions and methods for preventative treatments for mucosal associated ailments |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA907737B (en) * | 1989-09-29 | 1991-07-31 | Nisshin Oil Mills Ltd | Stable immunogen composition for oral administration |
| US6231870B1 (en) * | 1995-06-02 | 2001-05-15 | Uab Research Foundation | Oral administration of pneumoccal antigens |
| JPH0680575A (ja) * | 1991-03-05 | 1994-03-22 | Meiji Milk Prod Co Ltd | 経口免疫賦活剤 |
| ES2262181T3 (es) | 1996-05-31 | 2006-11-16 | National University Of Ireland, Maynooth | Il-12 como adyuvante en la vacuna contra la especie bordetella pertussis. |
| EP0988053A1 (en) | 1997-06-11 | 2000-03-29 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| WO1999012416A1 (en) * | 1997-09-09 | 1999-03-18 | The Trustees Of Columbia University In The City Of New York | T-independent conjugate-vaccines |
| US6153182A (en) | 1997-12-19 | 2000-11-28 | Uab Research Foundation | Lymphotactin as an adjuvant |
| PL341697A1 (en) | 1997-12-23 | 2001-04-23 | Genesis Res & Dev Corp Ltd | Compositions derived from mycobacterium vaccae and methods of using them |
| GB9727262D0 (en) * | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| GB9801870D0 (en) * | 1998-01-28 | 1998-03-25 | Raby Limited | Vaccine composition |
| DE69942214D1 (de) | 1998-02-05 | 2010-05-12 | Glaxosmithkline Biolog Sa | Verfahren zur Reinigung oder Herstellung der MAGE Protein |
| SE9800615D0 (sv) * | 1998-02-27 | 1998-02-27 | Ingvar Sjoeholm | Mucosal microparticle conjugate vaccine |
| US5985264A (en) * | 1998-03-05 | 1999-11-16 | The Medical College Of Ohio | IL-12 Stimulation of Neonatal immunity |
| CN1298307A (zh) | 1998-03-05 | 2001-06-06 | 俄亥俄医学院 | 通过鼻内接种il－12加强免疫性 |
| FR2776521B1 (fr) * | 1998-03-27 | 2000-12-15 | Pf Medicament | Utilisation de conjugues p40 actifs par voie nasale |
| EP1087788A1 (fr) * | 1998-06-26 | 2001-04-04 | Aventis Pasteur | Immunisation a ciblage mucosal |
| AR020102A1 (es) | 1998-07-30 | 2002-04-10 | Ucb Sa | Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento |
| GB9909077D0 (en) | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
| US7223398B1 (en) * | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| US20020044926A1 (en) * | 1999-12-10 | 2002-04-18 | Gregor Reid | Oral administration of lactobacillus for the treatment and prevention of urogenital infection |
| AUPQ761200A0 (en) * | 2000-05-19 | 2000-06-15 | Hunter Immunology Limited | Compositions and methods for treatment of mucosal infections |
| EP1303300B1 (en) * | 2000-06-19 | 2010-08-11 | Hunter Immunology Limited | Compositions and methods for treatment of candidiasis |
| NZ523995A (en) * | 2000-08-08 | 2005-03-24 | Genesis Res & Dev Corp Ltd | Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
-
2000
- 2000-05-19 AU AUPQ7612A patent/AUPQ761200A0/en not_active Abandoned
-
2001
- 2001-05-21 WO PCT/AU2001/000588 patent/WO2001087332A1/en not_active Ceased
- 2001-05-21 CN CN01811367A patent/CN1437480A/zh active Pending
- 2001-05-21 EP EP01931225A patent/EP1305042B1/en not_active Expired - Lifetime
- 2001-05-21 CA CA2409813A patent/CA2409813C/en not_active Expired - Lifetime
- 2001-05-21 BR BR0110971-5A patent/BR0110971A/pt not_active Application Discontinuation
- 2001-05-21 AT AT01931225T patent/ATE535284T1/de active
- 2001-05-21 US US10/276,829 patent/US8637051B2/en not_active Expired - Fee Related
- 2001-05-21 JP JP2001583799A patent/JP5567756B2/ja not_active Expired - Fee Related
- 2001-05-21 KR KR1020027015631A patent/KR20030019389A/ko not_active Withdrawn
-
2012
- 2012-03-30 JP JP2012080832A patent/JP2012153706A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003533489A5 (enExample) | ||
| Mayr et al. | Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157: H7 bacterial ghosts protects mice against lethal challenge | |
| JP2012153706A (ja) | 粘膜感染症の処置のための組成物および方法 | |
| LeBlanc et al. | Induction of a humoral immune response following an Escherichia coli O157: H7 infection with an immunomodulatory peptidic fraction derived from Lactobacillus helveticus-fermented milk | |
| US20030180260A1 (en) | Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor | |
| WO2002016554A1 (en) | Probiotics products containing lactic acid bacterium | |
| WO2000056359A3 (en) | Vaccine against streptococcus pneumoniae | |
| DE69224814D1 (de) | Den darm kolonisierende laktobacillen | |
| JP2018520677A5 (enExample) | ||
| AU2007316091B2 (en) | Prophylactic tuberculosis vaccine | |
| NO933037L (no) | Fremstilling og anvendelse av formalinavlivede e. coliorganismer som uttrykker kolonisasjonsfaktor-antigen (cfa), til vaksinasjon mot tarminfeksjon/diare hos mennesker foraarsaket av tarmtoksigenet e. coli-bakterier | |
| Kyd et al. | Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview | |
| JPWO2020073088A5 (enExample) | ||
| AU2001258060B2 (en) | Compositions and methods for treatment of mucosal infections | |
| Silvan et al. | Modulation of inflammation and oxidative stress in Helicobacter pylori infection by bioactive compounds from food components | |
| JP2004507440A5 (enExample) | ||
| Clancy | The cocci | |
| JP2007512815A (ja) | 微生物用の凍結保護剤 | |
| RU2339389C2 (ru) | Способ профилактики назофарингиального носительства патогенной микрофлоры | |
| Stjernquist-Desatnik et al. | Protective effect of heterologous gram-positive vaccine against lethal upper respiratory tract infection with type M50 group A streptococci in mice | |
| Wainwright | Biological control of microbial infections and cancer in humans: Historical use to future potential | |
| Cobo et al. | Prosthetic valve endocarditis due to Actinobacillus actinomycetemcomitans: a review of 36 cases | |
| Tsukada et al. | Serum level of Pseudomonas aeruginosa-specific IgA in patients with chronic lower respiratory tract infection and its clinical significance | |
| JP2003534250A5 (enExample) | ||
| AU2001258060A1 (en) | Compositions and methods for treatment of mucosal infections |